Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF).
In 2021, Lumenis announced that the FDA has granted De Novo authorization for Lumenis’ newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD).
The multi-center, double-blinded, randomized controlled FDA trial showed that Lumenis’ IPL with patented Optimal Pulse Technology (OPT®) significantly improved tear breakup time, meibum quality, and meibomian gland expressibility. The clinical trial joins a long list of studies of Lumenis’ IPL with OPT® that have shown the same results, as well as reduction of inflammatory markers.
Ophthalmologist deals with dry eye every day, but unless we address the underlying inflammation, it’s difficult to meaningfully impact the disease. Lumenis’ IPL with patented Optimal Pulse Technology (OPT®) helps ophthalmologist to address the inflammation, as shown in Lumenis’ IPL clinical trials, and improves signs of dry eye disease due to MGD, positioning it as a valuable tool in dry eye toolkit.